nach oben

Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen

Erschienen in:

04.01.2018 | Originalien

Menopausale Hormontherapie 15 Jahre post WHI: Sicherheit geht vor

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Publikation des Östrogen-Gestagen-Arms der WHI-Studie 2002 (WHI: Women’s Health Initiative) war von Fehlinterpretationen der Studienresultate gekennzeichnet. Anhand der Post-WHI-Literatur zur menopausalen Hormontherapie (MHT) werden die tatsächlichen und vermeintlichen Risiken für Brustkrebs, venöse Thromboembolien, Schlaganfall und koronare Herzkrankheit analysiert. Die sich daraus ableitenden Sicherheitsmaßnahmen, wie der Beginn der MHT in der Peri- oder frühen Postmenopause („window of opportunity“), die transdermale Östrogenadministration und die Auswahl eines neutralen Progestogens, können das Risiko minimieren und den Nutzen bei therapeutischen und präventiven Indikationen maximieren.

Vorheriger Artikel Bewegungs- und Physiotherapie bei Osteoporose

Nächster Artikel Mitteilungen des Magnesium- und Osteoporoseforums Bad Radkersburg

Langer RD (2017) The evidence base for Hormone Replacement Therapy (HRT): what can we believe? Climacteric 20:91–96CrossRefPubMed

Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRef

The Women’s Health Initiative Study Group (1998) Design of the women’s health initiative clinical trial and observational study. Control Clin Trials 19:61–109CrossRef

Shapiro S (2003) Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women’s Health Initiative randomized controlled trial. Climacteric 6(4):302–310. (discussion 310–313)CrossRefPubMed

National Institutes of Health (2002) NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, lack of overall benefit. Press release. http://www.nhlbi.nih.gov/whi/pr_02-7-9.pdf. Zugegriffen: 29. Okt. 2016

Anderson GL, Chlebowski RT, Rossouw JE et al (2006) Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 55:103–115CrossRefPubMed

Baber RJ, Panay N, Fenton A, Writing Group (2016) IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19(2):109–150CrossRefPubMed

Women’s Health Initiative Steering Committee, Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRef

North American Menopause Society (2017) Menopause glossary. https://www.menopause.org/for-women/menopause-glossary. Zugegriffen: 1. Okt. 2017

10.

Fournier A, Berrino F, Clavell-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111CrossRefPubMed

11.

Cordina-Duverger E, Truong T, Anger A et al (2013) Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLOS ONE 8:e78016CrossRefPubMedPubMedCentral

12.

Lyytinen H, Pukkala E, Ylikorkala O (2009) Breast cancer risk in postmenopausal women using estradiol—progestogen therapy. Obstet Gynecol 113:65–73CrossRefPubMed

13.

Renoux C, Dell’Aniello S, Suissa S (2010) Hormone replacement therapy and the risk of venous thromboembolism: a population based study. J Thromb Haemost 8:979–986PubMed

14.

Canonico M, Fournier A, Carcaillon L et al (2010) Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 30:340–345CrossRefPubMed

15.

Canonico M, Oger E, Conard J et al (2006) Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 4:1259–1265CrossRefPubMed

16.

Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olié V, Scarabin PY (2010) Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 17(6):1122–1127CrossRefPubMedPubMedCentral

17.

Olié V, Canonico M, Scarabin PY (2010) Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 17(5):457–463CrossRefPubMed

18.

Henderson VW, Lobo RA (2012) Hormone therapy and the risk of stroke: perspectives 10 years after the Women’s Health Initiative trials. Climacteric 15:229–234CrossRefPubMedPubMedCentral

19.

Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368CrossRefPubMed

20.

Boardman HM, Hartley L, Eisinga A et al (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002229.pub4 PubMed

21.

Renoux C, Dell’aniello S, Garbe E et al (2010) Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340:c2519CrossRefPubMed

22.

Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, Elbaz A, Scarabin PY (2016) Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke 47(7):1734–1741CrossRefPubMedPubMedCentral

23.

Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 325(11):756–762CrossRefPubMed

24.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280(7):605–613CrossRefPubMed

25.

Clarkson TB (1994) Estrogens, progestins, and coronary heart disease in cynomolgus monkeys. Fertil Steril 62(6 Suppl 2):147S–151SPubMed

26.

Adams MR, Williams JK, Clarkson TB, Jayo MJ (1991) Effects of oestrogens and progestogens on coronary atherosclerosis and osteoporosis of monkeys. Baillieres Clin Obstet Gynaecol 5(4):915–934CrossRefPubMed

27.

Hu P, Greendale GA, Palla SL et al (2006) The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the Postmenopausal Estrogen Progestin Intervention (PEPI) trial. Atherosclerosis 185:347–352CrossRefPubMed

28.

Galis ZS, Sukhova GK, Lark MV, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493–2503CrossRefPubMedPubMedCentral

29.

ELITE Research Group, Hodis HN, Mack WJ, Henderson VW et al (2016) Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 374(13):1221–1231CrossRef

Titel: Menopausale Hormontherapie 15 Jahre post WHI: Sicherheit geht vor
Publikationsdatum: 04.01.2018
Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen / Ausgabe 1/2018
Print ISSN: 2412-8260
Elektronische ISSN: 2412-8287
DOI: https://doi.org/10.1007/s41970-017-0017-y

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Editorial

News-Screen Osteologie

Bewegungs- und Physiotherapie bei Osteoporose

News-Screen Rheumatologie

News-Screen Orthopädie & Traumatologie

Fibröse Dysplasie